RT Journal Article
SR Electronic
T1 Exploring Associations with Severe Hypoxemic Respiratory Failure in COVID-19 Patients upon Admission: A Model for Severe Hypoxemic Respiratory Failure in 329 Unvaccinated, Hospitalized COVID-19 Patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.11.05.21265970
DO 10.1101/2021.11.05.21265970
A1 Davis, John W.
A1 Wang, Beilin
A1 Tomczak, Ewa
A1 Fu, Chia-Chi
A1 Harmouch, Wissam
A1 Reynoso, David R.
A1 Keiser, Philip
A1 Cabada, Miguel M.
YR 2021
UL http://medrxiv.org/content/early/2021/11/09/2021.11.05.21265970.abstract
AB Objective The severe acute respiratory syndrome-Coronavirus-2 (SARS-CoV-2) has caused a pandemic claiming more than 4 million lives worldwide. Overwhelming Coronavirus-Disease-2019 (COVID-19) respiratory failure placed tremendous demands on healthcare systems increasing the death toll. Cost-effective prognostic tools to characterize COVID-19 patients’ likely to progress to severe hypoxemic respiratory failure are still needed.Design We conducted a retrospective cohort study to develop a model utilizing demographic and clinical data collected in the first 12-hours admission to explore associations with severe hypoxemic respiratory failure in unvaccinated and hospitalized COVID-19 patients.Setting University based healthcare system including 6 hospitals located in the Galveston, Brazoria and Harris counties of Texas.Participants Adult patients diagnosed with COVID-19 and admitted to one of six hospitals between March 19th and June 31st, 2020.Primary outcome The primary outcome was defined as reaching a WHO ordinal scale between 6-9 at any time during admission, which corresponded to severe hypoxemic respiratory failure requiring high-flow oxygen supplementation or mechanical ventilation.Results We included 329 participants in the model cohort and 62 (18.8%) met the primary outcome. Our multivariable regression model found that lactate dehydrogenase (OR 3.38 (95% CI 2.04-5.59)), qSOFA score (OR: 2.24 (95% CI 1.22-4.12)), neutrophil to lymphocyte ratio (OR:1.08 (95% CI 1.02-1.14)), age (OR: 1.04 (95% CI 1.02-1.07)), BMI (OR: 1.08 (95% CI1.03-1.13)), oxygen saturation or admission SpO2 (OR: 0.91 (95% CI 0.83-0.99)), and admission date (OR: 0.99 (95% CI 0.98-0.99)). The final model showed an area under curve (AUC) of 0.85. The sensitivity analysis and point of influence analysis did not reveal inconsistencies.Conclusions Our study demonstrated that a combination of accessible demographic and clinical information provide a powerful predictive tool to identify subjects with CoVID-19 likely to progress to severe hypoxemic respiratory failure.STRENGTHS⍰ Our study utilized objective and measurable demographic and clinical information regularly available in healthcare settings even among patients unable to communicate.⍰ Our primary outcome corresponds to WHO ordinal score which would allow compare our results to other studies and in other settings.⍰ Our model could serve as an effective point of service tool during early admission to assist in clinical management and allocation of resources to unvaccinated patients.LIMITATIONS⍰ Our study is a retrospective study of unvaccinated COVID19 patients, and validation of our prediction model in the rest of our study population is still needed.⍰ In addition, testing our model in a more recent cohort after emergence of new SARS-CoV-2 variants will be needed to assess its robustness.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo extramural fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by UTMB Institutional Review Board (20-0126) and the Texas Department of Criminal Justice (TDCJ) Institutional Review Board (#819-RM20).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSAS Code and de-identified data will be published at Dryad, an online repository.(SARS-CoV-2)Severe acute respiratory syndrome-Coronoavius-2(COVID-19)Coronaviurs-Disease-19(WHO)World Health Organization(CDC)Center of Disease Control and Prevention(UTMB)University of Texas Medical Branch(TDCJ)Texas Department of Criminal Justice(GCS)Glawgow coma scale(qSOFA)Quick Sequential Organ Failure Assessment(NLR)Neutrophil to lymphocyte ratio(LDH)Lactate Dehydrogenase(CRP)C-reactive protein(BMI)Body mass index(IQR)Interquartile range(SD)Standard deviation(AIC)Stepwise Akaike Information Criteria(GOF)Goodness of fit(ROC)Receiver operating characteristics curve(AUC)Area under the curve